Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NYSE:ANRO NASDAQ:DRUG NASDAQ:IMUX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.90+1.1%$2.22$0.98▼$4.46$648.89M0.466.92 million shs8.64 million shsANROAlto Neuroscience$21.57+0.6%$22.71$2.15▼$28.44$752.06M1.22335,972 shs272,048 shsDRUGBright Minds Biosciences$60.95-1.0%$81.58$23.17▼$123.75$599.21M-5.53397,187 shs658,916 shsIMUXImmunic$13.86+6.0%$11.92$5.06▼$15.77$178.03M1.37237,649 shs195,588 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics+5.62%-7.84%-18.26%-21.67%+29.66%ANROAlto Neuroscience+8.68%+6.54%-13.33%-4.52%+756.11%DRUGBright Minds Biosciences+0.02%-17.87%-27.27%-14.49%+121.87%IMUXImmunic+11.61%-9.42%+9.83%+11.71%+50.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.90+1.1%$2.22$0.98▼$4.46$648.89M0.466.92 million shs8.64 million shsANROAlto Neuroscience$21.57+0.6%$22.71$2.15▼$28.44$752.06M1.22335,972 shs272,048 shsDRUGBright Minds Biosciences$60.95-1.0%$81.58$23.17▼$123.75$599.21M-5.53397,187 shs658,916 shsIMUXImmunic$13.86+6.0%$11.92$5.06▼$15.77$178.03M1.37237,649 shs195,588 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics+5.62%-7.84%-18.26%-21.67%+29.66%ANROAlto Neuroscience+8.68%+6.54%-13.33%-4.52%+756.11%DRUGBright Minds Biosciences+0.02%-17.87%-27.27%-14.49%+121.87%IMUXImmunic+11.61%-9.42%+9.83%+11.71%+50.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.69Moderate Buy$8.52348.54% UpsideANROAlto Neuroscience 2.70Moderate Buy$35.2563.46% UpsideDRUGBright Minds Biosciences 2.86Moderate Buy$143.83135.99% UpsideIMUXImmunic 3.00Buy$47.57243.23% UpsideCurrent Analyst Ratings BreakdownLatest IMUX, ANRO, ALLO, and DRUG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026DRUGBright Minds Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$145.005/29/2026IMUXImmunic Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/27/2026ANROAlto Neuroscience HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.005/22/2026ANROAlto Neuroscience Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/22/2026IMUXImmunic Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/22/2026IMUXImmunic B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $27.005/20/2026DRUGBright Minds Biosciences Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$190.00 ➝ $220.005/18/2026ANROAlto Neuroscience Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$38.00 ➝ $36.005/14/2026IMUXImmunic Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.005/14/2026ANROAlto Neuroscience WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$21.00 ➝ $24.005/11/2026ANROAlto Neuroscience HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$20K32,789.25N/AN/A$1.30 per share1.46ANROAlto NeuroscienceN/AN/AN/AN/A$4.87 per shareN/ADRUGBright Minds BiosciencesN/AN/AN/AN/A$8.33 per shareN/AIMUXImmunicN/AN/AN/AN/A($0.55) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$190.89M-$0.77N/AN/AN/AN/A-56.45%-40.36%8/12/2026 (Estimated)ANROAlto Neuroscience-$63.24M-$2.42N/AN/AN/AN/A-47.22%-38.81%8/12/2026 (Estimated)DRUGBright Minds Biosciences-$8.74M-$2.44N/AN/AN/AN/A-20.58%-20.25%8/13/2026 (Estimated)IMUXImmunic-$97.17M-$5.58N/AN/AN/AN/A-220.75%-132.04%8/6/2026 (Estimated)Latest IMUX, ANRO, ALLO, and DRUG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q2 2026DRUGBright Minds Biosciences-$0.8633-$0.80+$0.0633-$0.80N/AN/A5/13/2026Q1 2026ALLOAllogene Therapeutics-$0.19-$0.18+$0.01-$0.18$0.00 millionN/A5/13/2026Q1 2026ANROAlto Neuroscience-$0.56-$0.80-$0.24-$0.80N/AN/A5/13/2026Q1 2026IMUXImmunic-$0.71-$1.08-$0.37-$1.08N/AN/A3/16/2026Q4 2025ANROAlto Neuroscience-$0.56-$0.45+$0.11-$0.45N/AN/A3/12/2026Q4 2025ALLOAllogene Therapeutics-$0.25-$0.17+$0.08-$0.17$0.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/AANROAlto NeuroscienceN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.659.65ANROAlto Neuroscience0.0720.5220.52DRUGBright Minds BiosciencesN/A81.4781.47IMUXImmunicN/A4.924.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%ANROAlto NeuroscienceN/ADRUGBright Minds Biosciences40.52%IMUXImmunic51.82%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%ANROAlto Neuroscience11.25%DRUGBright Minds Biosciences42.66%IMUXImmunic5.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310345.15 million299.60 millionOptionableANROAlto NeuroscienceN/A35.09 million31.15 millionN/ADRUGBright Minds BiosciencesN/A9.73 million5.58 millionNot OptionableIMUXImmunic7013.62 million12.87 millionOptionableIMUX, ANRO, ALLO, and DRUG HeadlinesRecent News About These CompaniesImmunic to Participate in Investor, Industry and Scientific Conferences in JuneJune 10 at 6:30 AM | prnewswire.comImmunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of "Buy" by AnalystsJune 6, 2026 | americanbankingnews.comImmunic presents new vidofludimus calcium data at multiple sclerosis conferenceMay 28, 2026 | proactiveinvestors.comImmunic Highlights Positive Phase 2 CALLIPER MS DataMay 28, 2026 | tipranks.comImmunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple SclerosisMay 28, 2026 | prnewswire.comImmunic names Erik Lundgren as CEO as it advances Phase 3 MS trialsMay 27, 2026 | proactiveinvestors.comImmunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive OfficerMay 27, 2026 | prnewswire.comImmunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readoutMay 19, 2026 | proactiveinvestors.comAnalysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX) and Immunic (IMUX)May 19, 2026 | theglobeandmail.comImmunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of DirectorsMay 19, 2026 | prnewswire.comImmunic (IMUX) Gets a Buy from LifeSci CapitalMay 18, 2026 | theglobeandmail.comIs Immunic (NASDAQ:IMUX) In A Good Position To Deliver On Growth Plans?May 17, 2026 | finance.yahoo.comImmunic advances Phase 3 MS program, eyes topline data by year-endMay 13, 2026 | proactiveinvestors.comImmunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | prnewswire.comImmunic: Saved By A 200 Million Private PlacementMay 12, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Immunic (IMUX) and Hinge Health, Inc. Class A (HNGE)May 8, 2026 | theglobeandmail.comImmunic to Participate in Investor and Medical Conferences in MayApril 30, 2026 | prnewswire.comImmunic Appoints Veteran Neurology Leader as Chief Medical OfficerApril 30, 2026 | theglobeandmail.comImmunic appoints Michael Panzara as CMOApril 28, 2026 | thepharmaletter.comTImmunic (IMUX) price target increased by 920.41% to 54.64April 28, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 20263 Stocks to Own If Gas Prices Keep RisingBy Dan Schmidt | May 16, 2026IMUX, ANRO, ALLO, and DRUG Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.90 +0.02 (+1.06%) Closing price 04:00 PM EasternExtended Trading$1.88 -0.02 (-1.32%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Alto Neuroscience NYSE:ANRO$21.56 +0.14 (+0.63%) Closing price 03:59 PM EasternExtended Trading$21.49 -0.08 (-0.35%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.Bright Minds Biosciences NASDAQ:DRUG$60.95 -0.62 (-1.01%) Closing price 04:00 PM EasternExtended Trading$60.63 -0.32 (-0.53%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Immunic NASDAQ:IMUX$13.86 +0.79 (+6.04%) Closing price 04:00 PM EasternExtended Trading$13.42 -0.44 (-3.18%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
